<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352950</url>
  </required_header>
  <id_info>
    <org_study_id>20040145</org_study_id>
    <nct_id>NCT00352950</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>An Open-Label Clinical Trial Evaluating the Safety and Pharmacodynamics of Sirolimus and Panitumumab in Subjects With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      To determine the dose and schedule of sirolimus when given in combination with panitumumab in
      adult subjects with Stage IIIB/IV NSCLC
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2006</start_date>
  <completion_date>February 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety within the first 3 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic analysis of mTOR</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Oncology</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 954/Panitumumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically- or cytologically-confirmed diagnosis of stage IIIB or IV Non-Small
             Cell Lung Cancer

          -  Received only one prior treatment (not including radiation)

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors Group (RECIST)
             guidelines

          -  Life expectancy of ≥ 4 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematologic, renal and hepatic function

          -  Serum-fasting cholesterol ≤ 300 mg/dL Serum-fasting triglycerides ≤ 2.5 X ULN
             Exclusion Criteria:

          -  Brain metastases requiring treatment

          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis or pulmonary fibrosis on baseline

          -  Systemic chemotherapy, radiotherapy, hormonal therapy or immunotherapy within 30 days
             before enrollment

          -  Prior epidermal growth factor receptor targeting agents with the exception of the
             small molecule EGFr tyrosine kinase inhibitors

          -  Prior anti-tumor therapies including prior experimental agents or approved anti-tumor
             small molecules and biologics of short serum half-life (less than 1 week) within 30
             days before enrollment, or prior experimental or approved proteins/antibodies with
             longer serum half-life within 6 weeks before enrollment

          -  Prior therapy with sirolimus, sirolimus analogs

          -  Immunosuppressive agents within 28 days before enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 6, 2006</study_first_submitted>
  <study_first_submitted_qc>July 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2006</study_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>NSCLC, Lung cancer</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>mTOR</keyword>
  <keyword>Monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

